U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,151.87
    -146.36 (-0.76%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Aptinyx: Q4 Earnings Insights

·1 min read

Shares of Aptinyx (NASDAQ:APTX) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 51.22% year over year to ($0.20), which beat the estimate of ($0.24).

Revenue of $0 declined by 100.00% from the same period last year, which missed the estimate of $120,000.

Guidance

Aptinyx hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Mar 24, 2021

View more earnings on APTX

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.aptinyx.com%2F&eventid=2948429&sessionid=1&key=BE9996CA7D50B7BAC350DCFB9D849F76&regTag=&V2=false&sourcepage=register

Technicals

Company's 52-week high was at $6.47

Company's 52-week low was at $1.91

Price action over last quarter: down 4.17%

Company Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.